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ABSTRACT 
 
Tetrahydrofolate (THF) mediates DNA and RNA synthesis through 
production of purine and thymidylate precursors. During this process 
THF is reduced to the inactive dihydrofolate (DHF) and recycled back 
to the active DHF via a redox reaction, catalysed by dihydrofolate 
reductase (DHFR). DHFR inhibition prevents cellular growth, hence 
drug design at this locus is considered valuable with DHFR antagonists 
having clinical relevance in proliferative disease management. This 
study utilised methotrexate (MTX) as lead molecule in the design and 
optimisation of novel DHFR antagonists. PDB crystallographic 
deposition 1U72 (Cody et al., 2005) 
3
 describing the holo MTX: 
human DHFR complex was modelled in SYBYL-X® v1.2 (Tripos)  
and affinity of MTX for the cognate receptor measured in X-SCORE 
v1.2 (Wang et al.,1998)to establish baseline affinity. Structure activity 
data and 2D-topology maps generated in PoseView v1.1 (Stierand and 
Gastreich, 2011)
6
 guided the creation of 7 seeds in which moieties 
considered non-critical for binding and clinical effect were 
computationally modified using the GROW module of LigBuilder v1.2 
(Wang et al., 2000)
7
.Each of the 7 seeds yielded 200 novel structures 
which were classified according to pharmacophore structure, 
physiochemical parameter and binding affinity. This molecular cohort 
was assessed for Lipinski Rule compliance which reduced the total 
number of viable molecules to 177. These were rendered in UCSF 
Chimera v1.8 (Pettersen et al., 2004)
5
 and Accelerys Draw® 
v4.1(Accelrys Software Inc., 2013)
1
 for visualisation and 
pharmacophoric growth deduction. The optimal structures combining 
affinity and Lipinski Rule compliance from each pharmacophoric 
group were identified, which could be further optimised for in vitro 
validation on the premise that they hold promise as clinically use anti-
proliferative drugs. 
Introduction: 
Tetrahydrofolate a derivative of Vitamin B9, acts a 
one-carbon donor during reactions necessary for the synthesis 
of essential nucleotide precursors, thymidylate and 
methionine amongst other metabolites. At the end of these 
reactions, tetrahydrofolate becomes reduced to the 
insufficient folate form, dihydrofoalte. 
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Many of the enzymes which make use of 
tetrahydroflate recycle the dihydrofolate back to 
tetrahydrofolate. However the enzyme Thymidylate  
Synthase is the only enzyme utilising one-carbon-transfers 
that ultimately fails to reproduce tetrahydrofolate. It is the 
Dihydrofolate Reductase enzyme (DHFR) that recycles the 
dihydrofolate to tetrahydrofolate via a redox reaction in the 
presence of NADPH co-factor.  
Since the DHFR enzyme is solely responsible for 
maintaining the in-vitro necessary pools of tetrahydrofolate, 
this enzyme has a crucial role in supporting the production of 
DNA and RNA in all living organisms. Moreover, inhibition 
of this ubiquitous enzyme leads to cessation of cellular 
growth, hence making the DHFR enzyme an ideal target in 
humans for inhibiting proliferation in rapidly dividing cells. 
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The drug methotrexate targets the human DHFR, 
resulting in cell growth inhibition when it binds to this 
enzyme instead of Dihydrofolate. Apart from its indications 
in inflammatory diseases such as rheumatoid and psoriatic 
arthritis, MTX is to date the main antimetabolite used in 
chemotherapy since its FDA approval in 1953. 
It is against the background of this information that 
this study was carried out. The aim was to discover and 
optimise high in-silico binding affinity antifolate ligands for 
the hDHFR enzyme, with predicted oral bioavailability and 
the potential to be developed into clinically useful agents.  
 
Methodology: 
Molecular modelling was carried out in SYBYL-
X® v1.2 (Tripos). The holo hDHFR: MTX complex 
illustrated in Figure 1, was edited such that any water 
molecules considered as non-critical to binding were 
eliminated. The co-crystallized NADPH heteroatom’s and 
water molecules in the vicinity of the Ligand Binding Pocket 
(LBP) were retained. MTX as illustrated in Figure 2, was 
extracted from its LBP and exported, together with the apo 
DHFR receptor as illustrated in Figure 3, into X-SCORE v1.2 
(Wang et al.,1998) 7 for the baseline ligand binding affinity 
(pKd) for all novel structures designed in this study.  
 
Figure 1:hDHFR depicted in rainbow surface with MTX and 
NADPH. Image generated with  UCSF Chimera 
v1.8(Pettersen et al., 2004) 
 
Structure activity data from the literature (Cody et 
al., 2005)3 (Oefner et al., 1988)4 guided the creation of seed 
structures which are moleular fragments capable of sustaining 
structure directed growth. 7 seed structures were designed 
differing both in magintude and growing site loci, designated 
asHspc atoms as depicted in Figure 4 and Table 1.The 
designed structures ensured that the de novo deisgn exercise 
would explore maximal pharmacophoric space and novel 
structural breadth.  
De novo molecular growth was carried out in 
LigBuilder v1.2 (Wang et al., 2000)7. The POCKET 
algorithm of this programme was used to delineate the 3D 
LBP of the hDHFR enzyme depicted in Figures 5-7 based on 
the bioactive conformation of MTX to propose a general 
pharmacophoric structure on which all the novel structures 
generated would be based.  
 
Figure 2: MTX as 3D structure depicted in grey with 
heteroatoms. Image generated with UCSF Chimera v1.8 
(Pettersen et al., 2004) 
Figure 3: Apo hDHFR depictedaccording to strands (purple), 
helix (red), coils (yellow). Image generated with UCSF 
Chimera v1.8 (Pettersen et al) 
 
 
Using the GROW algorithm of LigBuilder v1.2 
(Wang et al., 2000)7 each seed structure was introduced into 
the LBP map, generated in the POCKET algorithm of  
LigBuilder v1.2 (Wang et al., 2000)7and allowed growth 
within its confines, initiating from the pre-designed growing 
site. 200 molecules were generated from each seed and were 
organized by the PROCESS algorithm of LigBuilder v1.2 
(Wang et al., 2000)7 into a molecular database with in which 
molecules were segregated into families according to LBA. 
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Physicochemical parameters; including logP, molecular 
weight and synthetic feasibility score were also included. The 
generated small molecules for each seed were filtered for 
Lipinski Rule compliance (Lipinski et al., 2001). This 
reduced molecular cohort was analysed from a 
pharmacophoric perspective with the pharmacophores 
specific to each family for each seed being identified.  
 
 
Figure 4: The 7 Seeds A-G; aligned in accordance to their magnitude with respect to MTX. Image generated with UCSF 
Chimera v1.8 (Pettersen et al., 2004) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: The delineated LBP produced by POCKET 
LigBuilder v1.2 (Wang et al., 2000)7. Atomic representations 
are as follows: Nitrogen atoms (Blue) represent hydrogen-
bond donor sites; oxygen atoms (Red) represent hydrogen-
bond acceptor sites and carbon atoms (Taupe) represent 
hydrophobic sites.Image generated with UCSF Chimera v1.8 
(Pettersen 
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Figure 6: The Pharmacophore model, produced by POCKET 
LigBuilder v1.2 (Wang et al., 2000)7. Atomic representations 
are as indicated in Figure 5 above 
 
 
Figure 7: MTX inside the delineated LBPproduced by 
POCKET LigBuilder v1.2 (Wang et al., 2000). Image 
generated with UCSF Chimera v1.8 (Pettersen et al., 2004) 
 
 
The optimal Lipinski Rule compliant (Lipinski et 
al., 2001) molecule from each family was identified. 
PoseView v1.1 (Stierand and Gastreich, 2011) was used in 
order to generate 2D topology maps describing the 
interactions between the specific molecular moieties of the 
selected optimal structures and amino acids forming the 
perimeter of the hDHFR LBP. The LBA and binding energy 
for the top selected ligands were also calculated using X-
SCORE v1.2 (Wang et al.,1998), the values of which are 
illustrated in Table 2. 
 
Results and Discussion  
From total of 1400 novel structures 177 were 
compliant with Lipinski’s Rule of 5 (Lipinski et al., 2001), 
the majority of which derived from seed A followed by seed 
G. These results are illustrated in Table 1. 
Seed A, the smallest seed, comprising exclusively 
the pyrimidine ring of MTX as illustrated in Figure 4, gave 
the maximum number of Lipinski rule compliant molecules 
with a total of 89 molecules from 10 different families. All 10 
families had at least one structure that was compliant with 
Lipinski’s rule of 5. The top selected molecule derived from 
Family 2 which generated the maximum number of Lipinski 
Rule of 5 (Lipinski et al., 2001).The top selected molecule 
Result_052 illustrated in Figure 8 had molecular weight of 
383 logP value of 3.2, pKd  value of 9.85 and a total of 5 and 
7 H-Bond donors and acceptors respectively. 
The selected ligand for seed A formed hydrogen 
bonds represented by dashed lines emanating from single 
pyrimidine ring, with Glu30, Ile115 and Ile7. The pyrimidine 
ring of the top selected molecule also formed π interactions 
with the hydrophobic amino acid Phe34. These hydrogen 
bonds and π interactions are the same as those forged by 
MTX via its pteridine ring. The ligands’ end terminal comes 
in contact with a hydrophobic pocket formed byIle60 and 
Phe3as depicted by the green spline segments. In MTX these 
amino acids are in contact with the bridge region. Another 
hydrogen bond was recognized to be formed with Try121 by 
the NH4 group at the end terminal which is not recognized in 
the generated complex of MTX.   
The pteridine ring of the top ligand for seed B, 
interacted with the same amino acids as this moiety did in the 
top selected ligand for seed A, with amino acids Phe34, Glu30, 
Val115 and Ile7 respectively. The bridge region did not 
interact significantly to binding. Growth at end terminal 
generated a pyridine ring fused with a benzene ring with 
various electronegative carbonyl groups attached to the 
pyridine ring. Asp21 interacted via a hydrogen bond with the 
hydroxyl group substituent to pyridine ring, as donated by the 
dashed line. The benzene ring interacts via π bonds with 
Phe31, while the end terminal occupies a hydrophobic pocket 
formed byPro61, Phe34, Ile60 and Phe31 as donated by the 
green spline segment. This gave the highest predicted binding 
affinity and energy as illustrated in Table 2. 
SeedC generated only 4 Lipinski’s rule compliant 
molecules, deriving from two different families. Result_163 
deriving from Family 5 was selected as the top ligand for 
seed C, with molecular weight of 476, log P of 4.05, pKd of 
9.73 and a total of 4 and 9 hydrogen bond donors and 
acceptors in total. 
The pteridine ring of Result_163, illustrated in 
Figure 10 interacted with Glu30, Ile115, Ile7 and Phe34 as 
described for the top ligands selected for seeds A and B. 
Binding differences arose at the binding interactions for the 
bridge and end terminal region, which occupied the 
hydrophobic pocket formed Pro61, Phe34, Ile60 and Phe31 as 
donated by the green spline segment. 
Seed D gave rise to only 3 Lipinski rule complaint 
molecules. Result_179 illustrated in Figure 10 was selected 
originating from Family 3 was selected as the top seed, with a 
molecular mass of 494, logP of 3.67, pKd   of 9.93 and a total 
of 4 H-bond donors and 9 H-Bond acceptors. This gave the 
highest predicted binding affinity and energy with values of 
7.10 and -9.69 respectively.   
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Table 1: Illustrating the number of accepted and number rejected molecules and families for each 4of the 7 seeds, depicted in the 
second column. Figures of seeds were generated with UCSF Chimera v1.8 (Pettersen et al., 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
Seed Structure 
Accepted Rejected 
Number of 
molecules 
Different 
families 
Number of 
molecules 
Different 
families 
A 
 
89 10 110 0 
B 
 
16 4 184 3 
C 
 
4 3 195 7 
D 
 
3 2 197 6 
E 
 
28 7 172 8 
F 
 
3 5 192 10 
G 
 
41 
 
7 160 
 
10 
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Figure 8: Complex of top ligand for seed A, Reulst_052 in 
apo-hDHFR, generated by PoseView (Stierand and 
Gastreich, 2011) 
 
 
Figure 9: Complex of top ligand for seed B, Result_125 in 
apo-hDHFR, generated by PoseView (Stierand and 
Gastreich, 2011) 
 
Figure 10: Complex of top ligand for seed C, Result_163 in 
apo-hDHFR, generated by PoseView (Stierand and 
Gastreich, 2011). 
 
 
 
The top ligand selected for seed D generated 
similar binding modalities in comparison with the top 
selected ligands for seeds A, B and C. The only difference 
was the absence a bond with Ile60that was part of the 
hydrophobic pocket as illustrated in Figure 11.  
 
Figure 11: Complex of top ligand for seed D, Result_179 in 
apo-hDHFR, generated by PoseView (Stierand and 
Gastreich, 2011) 
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Seed E generated a total of 28 Lipinski rule 
compliant molecules (Lipinski et al., 2001).  
Result_132 from Family 6 was selected as the top 
ligand with molecular weight of 495, logP of 4.19, pKd of 
9.97, 3 and 9 H-bond donors. This ligand interacted with the 
receptor throughGlu30, Ile115, Ile7 and Phe34amino acids that 
formed hydrogen bonds with the pteridine ring. Phe34, Ile60 
and Phe31 formed a hydrophobic pocket that was occupied 
with the bridge region and Arg70formed hydrogen bonds with 
the end terminal,as donated by dashed lines in Figure 12. 
 
Table 2: Illustrates the predicted pKd and binding energy for 
MTX and the top selected ligand for seeds A to G 
respectively 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Complex of top ligand for seed E, Result_132 in 
apo-hDHFR, generated by PoseView (Stierand and 
Gastreich, 2011) 
 
 
 
 
Figure 13: Complex of top ligand for seed F, Result_031 in 
apo-hDHFR, generated by PoseView (Stierand and 
Gastreich, 2011) 
 
 
 
 
On the other hand, seed F, resulted in only 8 
Lipinski rule compliant molecules.  Result_031, illustrated in 
Figure 14 was chosen from Family 2 as the top selected 
ligands, with molecular mass of 463, log P of 4.26, pKd  of 
9.98, 3 H-bond donors and 9 H-Bond acceptors. Result_031, 
as depicted in Figure 13, made contact with a hitherto 
unutilized   amino acid, specifically Arg28, which was noted 
Ligand  
Predicted binding 
affinity -log (Kd) 
Predicted binding 
energy kcal/mol 
MTX 6.73 -9.19 
Top selected ligand for 
Seed A 
6.83 -9.32 
Top selected ligand for 
Seed B 
7.16 -9.77 
Top selected ligand for 
Seed C 
7.10 -9.69 
Top selected ligand for 
Seed D 
7.49 -10.22 
Top selected ligand for 
Seed E 
7.54 -10.28 
Top selected ligand for 
Seed F 
7.02 -9.57 
Top selected ligand for 
Seed G 
7.82 -10.67 
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to form part of the hydrophobic pocket which formed part of 
a hydrophobic pocket occupied by the end terminal of the 
ligand. Seed F, the parent fragment of this specific molecule, 
was the most structurally similar to MTX from the seed 
population.  
Seed G was the only seed that represented the 
terminal glutamate tail.  This generated a substantial amount 
of Lipinski rule complaint molecules.  Result_017 was 
selected as the top ligand, with molecular weight of 463, logP 
of 3.49, pKd  of 9.98, H-bond donor and acceptor of 6 and 7 
respectively.  
Result_017 illustrated in Figure 14, differed from 
the other top selected ligands because it lacked of pteridine 
ring. This was replaced by a two aromatic ring system 
(naphthalene ring), with substitutions by an ammonium 
group, a carbonyl group and a hydrophilic chain.  
 
Figure 14: Complex of top ligand for seed G, Result_017 in 
apo-hDHFR, generated by PoseView (Stierand and 
Gastreich, 2011) 
 
 
 
Four hitherto unaccessed amino acids interacted 
with this ligand; Gly20 and Asp21 interacted via hydrogen 
bonds with the ammonium group, Tyr121 interacted via 
hydrogen bonds with the carbonyl group, while Leu22 formed 
part of a hydrophobic pocket which was occupied by the ring 
system. All other interactions, specifically with Ile60, Phe31, 
Phe34 and Arg70 had previously been observed with the top 
ranking molecules deriving from the other seed structures. 
 
Conclusion 
This rational drug design study was constructed in such a 
way that allowed molecular growth to occur within the 
confines of the LBP in a staggered fashion, implying 
different degrees of freedom. This was done in order to 
ensure the casting of as wide as possible of a pharmacophoric 
net that would ensure a cohort of molecules that was as 
structurally diverse as possible,  which is an asset in 
subsequent rounds of structure optimisation.  
In fact this study has achieved pharmacophoric 
diversity with a total of 82 structurally distinct families (n=10 
for seed A, n=7 for seed B, n=10 for seed C, n=8 for seed D, 
n=15 for seed E, n= 15 for seed F and n= 17 for seed G). 
Common to all in silico studies, this project will at its 
terminus provide a hypothesis; in this case, the hypothesis is 
that a preliminary cohort of high affinity molecules whose 
structure is based on a bioactive antagonist conformation of 
MTX and which have the propensity to oral bioavailability, 
has been designed de novo.  
                   An issue that must be raised is the robustness of 
this hypothesis. This study must be considered as a first step 
in a rational, logically well executed trajectory, towards the 
identification of a novel clinically useful entity. The caveat 
consequently, is ‘first step’ and it is in this context that the 
robustness of this hypothesis must be evaluated. 
 This study was carried out under a number of constraints the 
most pertinent of which was time. This study was also carried 
out in a static environment in which both ligand and receptor 
are considered as rigid entities, which clearly is not 
representing the in vivo scenario. However, irrespective of 
this, a number of precautions were taken in order to lay the 
foundations for the exercise of time consuming and 
computationally intense molecular dynamics simulations, 
which would impart in silico notion to both entities according 
to Newtonian physics. These precautions included molecular 
simplifications prior to drug design commencement. 
Specifically, redundant water molecules and ligands not 
considered essential to ligand binding were computationally 
edited from the pdb crystallographic deposition 1U72 (Cody 
et al., 2005)3. 
                      In a scenario in which this study was to be 
furthered, the initial hypothesis made would be validated 
through an in silico molecular dynamic simulating study, 
before being confirmed through in vitro assay techniques   
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